{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:29:14Z","timestamp":1771471754106,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00104-025-02246-7","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:59:08Z","timestamp":1739977148000},"page":"951-959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ist die zytoreduktive Chirurgie mit HIPEC ausreichend finanziert?","Is cytoreductive surgery with HIPEC adequately funded?"],"prefix":"10.1007","volume":"96","author":[{"given":"Can","family":"Yurttas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kalmbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Ansorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Bezmawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Blumenstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus W.","family":"L\u00f6ffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 L.","family":"Mihaljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Holderried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2246_CR1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1245\/s10434-023-14442-y","volume":"31","author":"AA Abreu","year":"2024","unstructured":"Abreu\u00a0AA, Farah\u00a0E, Nix\u00a0R et\u00a0al (2024) Cost Analysis and Financial Implications of a\u00a0Peritoneal Surface Malignancy Program in the USA. Ann Surg Oncol 31:630\u2013644","journal-title":"Ann Surg Oncol"},{"key":"2246_CR2","doi-asserted-by":"crossref","unstructured":"Brind\u2019amour A, Webb M, Parapini M et\u00a0al (2021) The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a\u00a0systematic review. Clin Exp Metastasis","DOI":"10.1007\/s10585-021-10074-2"},{"key":"2246_CR3","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","volume":"249","author":"TC Chua","year":"2009","unstructured":"Chua\u00a0TC, Yan\u00a0TD, Saxena\u00a0A et\u00a0al (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a\u00a0highly morbid procedure?: a\u00a0systematic review of morbidity and mortality. Ann Surg 249:900\u2013907","journal-title":"Ann Surg"},{"key":"2246_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","volume":"7","author":"D Cort\u00e9s-Guiral","year":"2021","unstructured":"Cort\u00e9s-Guiral\u00a0D, H\u00fcbner\u00a0M, Alyami\u00a0M et\u00a0al (2021) Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 7:91","journal-title":"Nat Rev Dis Primers"},{"key":"2246_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo\u00a0D, Demartines\u00a0N, Clavien\u00a0PA (2004) Classification of surgical complications: a\u00a0new proposal with evaluation in a\u00a0cohort of 6336 patients and results of a\u00a0survey. Ann Surg 240:205\u2013213","journal-title":"Ann Surg"},{"key":"2246_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet\u00a0P, Sugarbaker\u00a0PH (1996) Peritoneal-plasma barrier. Cancer Treat Res 82:53\u201363","journal-title":"Cancer Treat Res"},{"key":"2246_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.7326\/0003-4819-157-12-201212180-00003","volume":"157","author":"PJ Kaboli","year":"2012","unstructured":"Kaboli\u00a0PJ, Go\u00a0JT, Hockenberry\u00a0J et\u00a0al (2012) Associations between reduced hospital length of stay and 30-day readmission rate and mortality: 14-year experience in 129 Veterans Affairs hospitals. Ann Intern Med 157:837\u2013845","journal-title":"Ann Intern Med"},{"key":"2246_CR8","series-title":"Peritoneum","first-page":"113","volume-title":"Early postoperative CRP predicts major complications following cytoreductive surgery","author":"A Kartik","year":"2023","unstructured":"Kartik\u00a0A, M\u00fcller\u00a0C, Acs\u00a0M et\u00a0al (2023) Early postoperative CRP predicts major complications following cytoreductive surgery. Peritoneum, Bd. 8. CRS, and hyperthermic intraperitoneal chemotherapy (HIPEC). Pleura, S\u00a0113\u2013121"},{"key":"2246_CR9","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00104-010-1927-1","volume":"81","author":"M Kilian","year":"2010","unstructured":"Kilian\u00a0M, Hammerich\u00a0R, Langelotz\u00a0C et\u00a0al (2010) Hyperthermic intraperitoneal chemotherapy in the German DRG system. Analysis of case cost calculations of a\u00a0maximum care university. Chirurg 81:1005\u20131012","journal-title":"Chirurg"},{"key":"2246_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ejso.2020.01.020","volume":"46","author":"D Klos","year":"2020","unstructured":"Klos\u00a0D, Ri\u0161ko\u00a0J, Kriv\u00e1\u010dkov\u00e1\u00a0D et\u00a0al (2020) Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a\u00a0public insurance health care system\u2014Single centre study. Eur J Surg Oncol 46:607\u2013612","journal-title":"Eur J Surg Oncol"},{"key":"2246_CR11","doi-asserted-by":"crossref","unstructured":"Kusamura S, Barretta F, Yonemura Y et\u00a0al (2021) Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. JAMA Surg e206363:","DOI":"10.1001\/jamasurg.2020.6363"},{"key":"2246_CR12","doi-asserted-by":"crossref","unstructured":"Noiret B, Lenne X, Bruandet A et\u00a0al (2024) Should Cytoreductive Surgery Alone for Peritoneal Metastases of Colorectal Origin be Centralized? A\u00a0National Study of 4159 Procedures. Ann Surg Oncol","DOI":"10.1245\/s10434-024-15180-5"},{"key":"2246_CR13","doi-asserted-by":"crossref","unstructured":"Qu\u00e9net F, Elias D, Roca L et\u00a0al (2021) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE\u00a07): a\u00a0multicentre, randomised, open-label, phase\u00a03\u00a0trial. Lancet Oncol","DOI":"10.1016\/S1470-2045(20)30599-4"},{"key":"2246_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau\u00a0B, Lang\u00a0H, Koenigsrainer\u00a0A et\u00a0al (2024) Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase\u00a0III GASTRIPEC\u2011I Trial. J\u00a0Clin Oncol 42:146\u2013156","journal-title":"J Clin Oncol"},{"key":"2246_CR15","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1245\/s10434-020-09232-9","volume":"27","author":"D Roife","year":"2020","unstructured":"Roife\u00a0D, Powers\u00a0BD, Zaidi\u00a0MY et\u00a0al (2020) CRS\/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A\u00a0Retrospective Cohort Study of the US HIPEC Collaborative. Ann Surg Oncol 27:4996\u20135004","journal-title":"Ann Surg Oncol"},{"key":"2246_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0b013e318296c732","volume":"258","author":"K Slankamenac","year":"2013","unstructured":"Slankamenac\u00a0K, Graf\u00a0R, Barkun\u00a0J et\u00a0al (2013) The comprehensive complication index: a\u00a0novel continuous scale to measure surgical morbidity. Ann Surg 258:1\u20137","journal-title":"Ann Surg"},{"key":"2246_CR17","doi-asserted-by":"crossref","unstructured":"\u00dcberr\u00fcck L, Nadiradze G, Yurttas C et\u00a0al (2020) In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany. Ann Surg Oncol","DOI":"10.1245\/s10434-020-09301-z"},{"key":"2246_CR18","doi-asserted-by":"crossref","unstructured":"Van Der Zant FA, Kooijman BJL, Hentzen J et\u00a0al (2022) Impact of cumulative complications on 1\u2011year treatment-related healthcare costs in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Bjs Open 6:","DOI":"10.1093\/bjsopen\/zrac109"},{"key":"2246_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Van Driel","year":"2018","unstructured":"Van Driel\u00a0WJ, Koole\u00a0SN, Sikorska\u00a0K et\u00a0al (2018) Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N\u00a0Engl J Med 378:230\u2013240","journal-title":"N Engl J Med"},{"key":"2246_CR20","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","volume":"25","author":"V Verma","year":"2018","unstructured":"Verma\u00a0V, Sleightholm\u00a0RL, Rusthoven\u00a0CG et\u00a0al (2018) Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival. Ann Surg Oncol 25:2018\u20132026","journal-title":"Ann Surg Oncol"},{"key":"2246_CR21","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal\u00a0VJ, Bruin\u00a0S, Boot\u00a0H et\u00a0al (2008) 8\u2011year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426\u20132432","journal-title":"Ann Surg Oncol"},{"key":"2246_CR22","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal\u00a0VJ, Van Ruth\u00a0S, De Bree\u00a0E et\u00a0al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J\u00a0Clin Oncol 21:3737\u20133743","journal-title":"J. Clin. Oncol."},{"key":"2246_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5492\/wjccm.v11.i6.375","volume":"11","author":"AS Wajekar","year":"2022","unstructured":"Wajekar\u00a0AS, Solanki\u00a0SL, Patil\u00a0VP (2022) Postoperative complications and critical care management after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy: A\u00a0systematic review of the literature. World J Crit Care Med 11:375\u2013386","journal-title":"World J Crit Care Med"},{"key":"2246_CR24","doi-asserted-by":"publisher","first-page":"9086","DOI":"10.1245\/s10434-021-10254-0","volume":"28","author":"C Yurttas","year":"2021","unstructured":"Yurttas\u00a0C, Horvath\u00a0P, Fischer\u00a0I et\u00a0al (2021) A Prospective, Phase\u00a0I\/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma. Ann Surg Oncol 28:9086\u20139095","journal-title":"Ann Surg Oncol"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-025-02246-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-025-02246-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-025-02246-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T11:12:43Z","timestamp":1761304363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-025-02246-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2246"],"URL":"https:\/\/doi.org\/10.1007\/s00104-025-02246-7","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"16 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.W.\u00a0L\u00f6ffler ist Erfinder von Patenten die im Besitz von Immatics Biotechnologies sind und war als bezahlter Referent und Berater f\u00fcr Boehringer Ingelheim t\u00e4tig. Weiterhin gibt er an, von RanD S.p.A. in der Vergangenheit finanzielle Unterst\u00fctzung f\u00fcr wissenschaftliche Projekte sowie f\u00fcr die Teilnahme an internationalen Konferenzen erhalten zu haben. C.\u00a0Yurttas, S.\u00a0Kalmbach, E.\u00a0Ansorge, M.\u00a0Bezmawi, G.\u00a0Blumenstock, A.L.\u00a0Mihaljevic, C.\u00a0Ernst und M.\u00a0Holderried geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Tieren durchgef\u00fchrt. Die retrospektive Erfassung der Patient\/-innendaten erfolgte auf Basis des von der Ethikkommission der Universit\u00e4t T\u00fcbingen begutachteten Pr\u00fcfplan und ist unter der Projektnummer 053\/2023BO2 registriert.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}